Previous close | 128.00 |
Open | 128.00 |
Bid | 128.00 x 0 |
Ask | 128.10 x 0 |
Day's range | 128.00 - 128.90 |
52-week range | 111.60 - 134.50 |
Volume | |
Avg. volume | 122,340 |
Market cap | 30.016B |
Beta (5Y monthly) | 0.14 |
PE ratio (TTM) | 45.71 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 5.12 (4.00%) |
Ex-dividend date | 17 Apr 2024 |
1y target est | N/A |
JPMorgan has turned positive on Unilever (LON:ULVR), after several years of caution, but has taken a more cautious view on Nestle (SIX:NESN) as its earnings growth moderates. Unilever has instituted several changes over the past 12 months, analysts at JPMorgan said in a note dated May 23, which have soothed the bank’s concerns, including cultural change and corporate governance; market share underperformance through increased investments and execution focus; and portfolio transformation with disposals. This feeds a stronger FY24, and should give credence to Unilever is on the path to turnaround and contribute to the stock re-rating along with positive earnings revision.
Weight loss drugs are rising in popularity, and food companies are cooking up new ways to win over those consumers.
Nestle will market a new, $5 line of frozen pizzas and protein-enriched pastas in the United States which it says it designed specifically for people taking drugs such as Wegovy or Ozempic for weight loss. The world's biggest food company, which sells DiGiorno pizza and Stouffer's meals to major grocers, said it developed the new products with more protein, iron and calcium for people taking the wildly popular appetite-suppressing drugs, called GLP-1 agonists. Tom Moe, president of Nestle USA's meal division, said it will pitch the meals in a new brand, Vital Pursuit, as "food solutions" for people who want to complement their use of the drugs with "the right nutrition - high protein, good fiber, the right minerals," like potassium and vitamin C.